In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

Mycopathologia

Volumn 171, Issue 5, 2011, Pages 345-348

  Li, Houmin ^a   Qiao, Jianjun ^b   Wan, Zhe ^c   Zhang, Jianzhong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antifungal susceptibility; Drug interaction; Trichosporonasahii

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; NAPHTHALENE DERIVATIVE; TERBINAFINE;

ARTICLE; DRUG EFFECT; DRUG INTERACTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOSIS; TRICHOSPORON;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; NAPHTHALENES; TRICHOSPORON;

TRICHOSPORON ASAHII;

EID: 79953322834     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9384-4     Document Type: Article

References (20)

1. Ebright JR, Fairfax MR, Vazquez JA. Trichosporon asahii, a non-candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. Clin Infect Dis. 2001; 33: E28-30.
2. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004; 10(Suppl 1): 48-66.
3. Kamberi P, Atsuro H, Takayoshi T, Masaru N. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice. Chemotherapy. 1998; 44: 55-62.
4. Serena C, Mariné M, Pastor FJ, Nolard N, Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother. 2005; 55: 1020-3.
5. Clinical and laboratory standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2002.
6. Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia. 2008; 166: 121-32.
7. Serena C, Pastor FJ, Gilgado F, Mayayo E, Guarro J. Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother. 2005; 49: 497-502.
8. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990; 28: 1616-22.
9. Serena C, Gilgado F, Mariné M, Pastor FJ, Guarro J. Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother. 2006; 50: 2240-3.
10. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother. 2002; 46: 1144-6.
11. Mekha N, Sugita T, Ikeda R, Nishikawa A, Autthateinchai R, Poonwan N, Sawanpanyalert P. Genotyping and antifungal drug susceptibility of the pathogenic yeast Trichosporon asahii isolated from Thai patients. Mycopathologia. 2010; 169: 67-70.
12. Li H, Lu Q, Wan Z, Zhang J. In vitro combined activity of Amphoterincin B, Caspofungin, and voriconazole against clinical isolates of Trichosporon asahii. Int J Antimicrob Agents. 2010; 35: 550-2.
13. Franzot SP, Casadevall A. Pneumocandin L-743, 872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother. 1997; 41: 331-6.
14. Rubin MA, Carroll KC, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis. 2002; 34: 1160-1.
15. Denning DW. Echinocandin antifungal drugs. Lancet. 2003; 362: 1142-51.
16. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille J, Calandra T, Zanolari B, Marchetti O. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother. 2010; 54: 5303-15.
17. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother. 1995; 39: 1779-83.
18. Te Dorsthorst DT, Verweij PE, Meis JF, Punt NC, Mouton JW. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother. 2002; 46: 702-7.
19. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992; 15: 21-34.
20. Pore RS. Amphotericin B synergy testing by the FCST. Curr Microbiol. 1992; 24: 171-7.